← All trials
NCT04464850
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 29, 2020
- Primary completion
- Jan 31, 2021
- Completion date
- Jul 31, 2022
- First posted
- Jul 9, 2020
- Last posted
- Aug 11, 2020
- Enrollment
- 124
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Chiangmai UniversityLead sponsor
- Chiangmai UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.